Cargando…
Age-related macular degeneration: a target for nanotechnology derived medicines
Despite the fact that the retina is a fairly accessible portion of the central nervous system, there are virtually no treatments for early age-related macular degeneration (AMD). AMD is a degenerative retinal disease that causes progressive loss of central vision and is the leading cause of irrevers...
Autores principales: | Birch, David G, Liang, Fong Qi |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673815/ https://www.ncbi.nlm.nih.gov/pubmed/17722514 |
Ejemplares similares
-
Nanotechnology for Age-Related Macular Degeneration
por: Yang, Bo, et al.
Publicado: (2021) -
Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
por: Fong, Angie HC, et al.
Publicado: (2013) -
Targeting MAPK Signaling in Age-Related Macular Degeneration
por: Kyosseva, Svetlana V.
Publicado: (2016) -
Pharmacogenetics and Age-Related Macular Degeneration
por: Schwartz, Stephen G., et al.
Publicado: (2011) -
Prevention of age-related macular degeneration
por: Wong, Ian Yat Hin, et al.
Publicado: (2010)